Study Cross-reactivity & COVID-19 Vaccine Responses!

Published on 05/04/2022

JPT has added exciting new tools to its already unrivalled range of SARS-CoV-2 research products. The new tools cover a highly immunogenic & conserved section of the SARS-CoV-2 spike fusion-peptide (FP) region. Recent publications have reported not only that there are dominant T-cell epitopes in the FP region, but also that responses to these are induced very effectively by the Pfizer-Biontech BNT162b2 (Comirnaty) vaccine^{1, 2 ,3}. T-cell responses to the FP region may, therefore, hold important clues for the understanding of SARS-CoV-2-specific immunity!

Please check out our new products :

1. PepMix SARS-CoV-2 (Spike Fusion-Peptide)

This novel PepMix peptide pool with a total of 28 peptides provides any possible sub-sequence of 11 - 17 amino acids length within SARS-CoV-2 spike814-830 and as such covers any conceivable CD4 or CD8 T-cell epitope within this sequence stretch. As a result, this peptide pool will be of particular interest for research into SARS-CoV-2 T-cell reactivity induced by vaccines or prior coronavirus exposure and cross reactivity.

2. SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD)

This 15-amino-acid single peptide spans SARS-CoV-2 spike816-830 and was used in a recent publication by Loyal et al. ¹

3. Biotinylated SARS-CoV-2 Antigen Peptide Spike Fusion (Biotin-SFIEDLLFNKVTLAD)

This is the biotinylated version of the single 15-amino-acid peptide. It will be useful for binding assays such as ELISPOT, ICS, cytotoxity, or proliferation assays.

Any questions?

Our dedicated customer service support is happy to provide further information, help, and support.

We are looking forward to talking to you!

References:

1. Loyal et al., Science (2021) - PMID: 34465633

2. Ong et al. Computational & Structural Biotechnology Journal (2021) - PMID: 33398234

3. Woldemeskel et al., Clinical Trial in Journal of Clinical Investigation (2022) - PMID: 35061630